Improvement in Dermatomyositis Rash Associated With the Use of Antiestrogen Medication

Sereda, A.D.; Werth, Victoria P.

doi:10.1001/archderm.142.1.70

Cited by 40 publications

(21 citation statements)

References 30 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, estrogen receptor antagonists have been used clinically to modulate pro-and anti-inflammatory cytokines in both mice and women with breast cancer [19,20]. Estrogen receptor antagonists decreased autoimmune symptoms in a murine model of systemic lupus erythematosus and in two women who had autoimmune dermatomyositis [21,22]. The immune effect seen in our subject population indicates the ability to respond to a HER-2/neu peptide based vaccine remains intact after hormonal modulation.…”

Section: Discussionmentioning

confidence: 81%

Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity

Coveler

Goodell

Webster

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Cancer vaccines may have the most potential for clinical impact when used in the adjuvant setting when tumor burden is at its lowest. Application of cancer vaccines in the adjuvant setting, however, requires integration of immunization with more standard cytotoxic or cytostatic therapies. Common adjuvant therapies for breast cancer patients, i.e. trastuzumab, bisphosphonates and hormonal agents are often administered over several years requiring concurrent administration of these drugs with active immunization. We questioned whether these common adjuvant therapies would impact a patient's ability to develop tumor specific immunity with vaccination. Immune parameters from 36 subjects were evaluated. We determined these adjuvant therapies have no impact on the ability to develop an immune response specific for HER-2/neu peptides (P>0.1) nor do they have an impact on the magnitude of T cell immunity developed with concurrent vaccination (P>0.1). This is the first report to show that the use of trastuzumab, bisphosphonates and hormonal therapy concurrent with cancer vaccine administration have no impact on either the generation or the magnitude of vaccine induced immunity.

show abstract

Section: Discussionmentioning

confidence: 81%

Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity

Coveler

Goodell

Webster

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…It is well known that ovarian or peripherallyderived estrogens may induce production of proinflammatory cytokines (i.e.TNF-alpha) by skin or immune cells [12][13]. Recently, Sereda et al [13] described the case of 2 young women with breast cancer, whose DM-associated skin manifestations significantly improved while taking antiestrogens such as docetaxel (a selective estrogen receptor modulator) and anastrazole (an aromatase inhibitor), probably because of inhibition of the TNF-alpha synthesis.…”

Section: Discussionmentioning

confidence: 99%

Dermatomyositis and cutaneous metastases from breast cancer: simultaneous development and parallel course

et al. 2009

View full text Add to dashboard Cite

Linking powered by eXtyles ABSTRACTThe association between dermatomyositis (DM) and various types of malignancies has been reported in several studies, with an estimated frequency of about 20% to 25%; cancer may appear before the onset of DM, concurrently with DM or after its onset. In the present report, the occurrence of typical DM in concomitance with development of skin metastases from previously treated breast cancer is described, suggesting the role of DM as paraneoplastic marker not only in association with the primary tumor but even in case of cutaneous involvement by cancer.

show abstract

“…Sereda and Werth observed an improvement in patients with dermatomyositis-associated skin eruptions while taking anti-estrogen medication (both tamoxifen and the aromatase inhibitor anastrozole) (62). Dermatomyositis is an autoimmune disease that occurs more often in women and causes inflammation of the skin and muscles.…”

Section: Anti-estrogenic Drugs: Connections With Autoimmune Disordersmentioning

confidence: 99%

Immunomodulatory effects of anti-estrogenic drugs

Ray¹,

M²

2012

Acta Pharmaceutica

View full text Add to dashboard Cite

Immunomodulatory effects of anti-estrogenic drugsThere are substantial experimental, epidemiological and clinical evidences that show that breast cancer pathology is influenced by endogenous estrogens. This knowledge is the foundation upon which endocrine deprivation therapy has been developed as a major modality for the management of breast cancer. Tamoxifen, which functions as a competitive partial agonist-inhibitor of estrogen at its receptor, has been widely used for more than three decades for adjuvant endocrine treatment in breast cancer. Currently, other effective drugs for endocrine therapy include raloxifene, different aromatase inhibitors (particularly third-generation agents) and luteinizing hormone-releasing hormone agonists. In recent years, a growing body of evidence suggests that these drugs can also act as immune modulators by altering the function of various leukocytes and the release of different cytokines. Moreover, there is evidence that anti-estrogens may prove to be beneficial in the treatment or prevention of some autoimmune diseases due to their effects on immune function. However, their immunopharmacological aspects in the present state of knowledge are not precisely comprehensible. Only a clear pathophysiological understanding could lead to an efficient strategy for breast cancer prevention and decrease in the mortality due to this disease.

show abstract

Improvement in Dermatomyositis Rash Associated With the Use of Antiestrogen Medication

Cited by 40 publications

References 30 publications

Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity

Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity

Dermatomyositis and cutaneous metastases from breast cancer: simultaneous development and parallel course

Immunomodulatory effects of anti-estrogenic drugs

Contact Info

Product

Resources

About